Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Hepatology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(18)30439-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Strategies to eliminate HBV infection: an update

  2020cites this paper
• Development of antiviral drugs against hepatitis B virus

  2019cites this paper
• Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection

  2019cites this paper
• Novel developments of hepatitis B: treatment goals, agents and monitoring tools

  2019cites this paper
• Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection.

  2019cites this paper
• Drugs in the Pipeline for HBV.

  2019cites this paper
• Review article: clinical pharmacology of current and investigational hepatitis B virus therapies

  2019cites this paper
• Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice

  2019cites this paper
• Assembly Properties of Hepatitis B Virus Core Protein Mutants Correlate with Their Resistance to Assembly-Directed Antivirals

  2018cites this paper
• Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus

  2018cites this paper
• Chronic hepatitis B virus infection.

  2018cites this paper
• Effect of Pegylated Interferon Add-On Therapy to Achieve Disease Remission in Patients with Chronic Hepatitis B

  2018cites this paper
• World Journal of Hepatology

  year unknowncites this paper